Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

被引：1
|
作者：
Rodon, Jordi [1 ]
Juric, Dejan [2 ]
Gonzalez-Angulo, Ana-Maria [3 ]
Bendell, Johanna [4 ]
Berlin, Jordan [5 ]
Bootle, Douglas [6 ]
Gravelin, Kathlene [7 ]
Huang, Alan [7 ]
Derti, Adnan [7 ]
Lehar, Joseph [7 ]
Wuerthner, Jens [6 ]
Boehm, Markus [6 ]
van Allen, Eliezer [8 ]
Wagle, Nikhil [8 ]
Garraway, Levi A. [8 ]
Yelensky, Roman [9 ]
Stephens, Philip J. [9 ]
Miller, Vincent A. [9 ]
Schlegel, Robert [7 ]
Quadt, Cornelia [6 ]
Baselga, Jose [10 ]
机构：
[1] Vail dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Vanderbilt Canc Ctr, Nashville, TN USA
[6] Novartis Pharma AG, Oncol Translat Med, Basel, Switzerland
[7] NIBR Inc, Oncol Translat Med, Cambridge, MA USA
[8] Broad Inst, Cambridge, MA USA
[9] Fdn Med Inc, Cambridge, MA USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-65
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB65
引用
收藏
页数：2
相关论文
共 44 条
  • [1] Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for Neuroendocrine Tumors?
    Noelting, S.
    Rentsch, J.
    Freitag, H.
    Briest, F.
    Schrader, J.
    Koenig, A.
    Prada, Aristizabal E. T.
    Siegmund, B.
    Auernhammer, C. J.
    Grabowski, P.
    NEUROENDOCRINOLOGY, 2016, 103 : 4 - 4
  • [2] BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
    Gobin, Berengere
    Baud'Huin, Marc
    Lamoureux, Francois
    Ory, Benjamin
    Charrier, Celine
    Lanel, Rachel
    Battaglia, Severine
    Redini, Francoise
    Lezot, Frederic
    Blanchard, Frederic
    Heymann, Dominique
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (04) : 784 - 796
  • [3] Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors
    Ando, Yuichi
    Iwasa, Satoru
    Takahashi, Shunji
    Saka, Hideo
    Kakizume, Tomoyuki
    Natsume, Kazuto
    Suenaga, Naoko
    Quadt, Cornelia
    Yamada, Yasuhide
    CANCER SCIENCE, 2019, 110 (03) : 1021 - 1031
  • [4] Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Diana G. Wang
    Dulce M. Barrios
    Victoria S. Blinder
    Jacqueline F. Bromberg
    Pamela R. Drullinsky
    Samuel A. Funt
    Komal L. Jhaveri
    Diana E. Lake
    Tomas Lyons
    Shanu Modi
    Pedram Razavi
    Michelle Sidel
    Tiffany A. Traina
    Linda T. Vahdat
    Mario E. Lacouture
    Breast Cancer Research and Treatment, 2020, 183 : 227 - 237
  • [5] PKC resistance in uveal melanoma is mediated by activation of AKT and reversed by BYL719, the PI3Kα inhibitor
    Musi, Elgilda
    Ambrosini, Grazia
    Schwartz, Gary K.
    CANCER RESEARCH, 2015, 75
  • [6] Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Wang, Diana G.
    Barrios, Dulce M.
    Blinder, Victoria S.
    Bromberg, Jacqueline F.
    Drullinsky, Pamela R.
    Funt, Samuel A.
    Jhaveri, Komal L.
    Lake, Diana E.
    Lyons, Tomas
    Modi, Shanu
    Razavi, Pedram
    Sidel, Michelle
    Traina, Tiffany A.
    Vandat, Linda T.
    Lacouture, Mario E.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 227 - 237
  • [7] In Vitro Anticancer Activity of PI3K Alpha Selective Inhibitor BYL719 in Head and Neck Cancer
    Keam, Bhumsuk
    Kim, Soyeon
    Ahn, Yong-Oon
    Kim, Tae Min
    Lee, Se-Hoon
    Kim, Dong-Wan
    Heo, Dae Seog
    ANTICANCER RESEARCH, 2015, 35 (01) : 175 - 182
  • [8] Anticancer activity of novel PI3K inhibitor BYL719 in head and neck cancer cell lines
    Keam, Bhumsuk
    Ahn, Yong-Oon
    Kim, Tae Min
    Lee, Se-Hoon
    Kim, Dong-Wan
    Heo, Dae Seog
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study.
    Gonzalez-Angulo, Ana M.
    Juric, Dejan
    Argiles, Guillem
    Schellens, Jan H. M.
    Burris, Howard A.
    Berlin, Jordan
    Middleton, Mark R.
    Schuler, Martin H.
    Van Geel, Robin
    Helgason, Thorunn
    Bootle, Douglas
    Boehm, Markus
    Goggin, Timothy K.
    Demanse, David
    Quadt, Cornelia
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent
    Fritsch, Christine M.
    Schnell, Christian
    Chatenay-Rivauday, Christian
    Guthy, Daniel A.
    De Pover, Alain
    Wartmann, Markus
    Brachmann, Saskia
    Maira, Sauveur-Michel
    Huang, Alan
    Quadt, Cornelia
    Hofmann, Francesco
    Caravatti, Giorgio
    CANCER RESEARCH, 2012, 72
12345